The major concern about the administration of antiarrhythmic drugs during pregnancy is related to their effect on fetal well-being. Even if teratogenic risks are higher during organogenesis in the first 8 weeks of pregnancy, after this period undesirable effects may include depression of uterine blood flow, interference with fetal growth and development, and interference with labor and delivery. Most drugs are secreted in the mother's milk, a fact that raises concern about the nursing infants. In this report we review the fetal risks related to the management of maternal arrhythmias during pregnancy showing that most patients can be treated with an excellent result for their babies.
|Translated title of the contribution||Fetal risks related to the administration of anti-arrhythmia drugs during pregnancy|
|Number of pages||10|
|Journal||Italian Heart Journal|
|Issue number||10 Suppl|
|Publication status||Published - Oct 2002|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine